Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Blood Flow Restriction Therapy in Patellofemoral Pain Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03717532
Recruitment Status : Terminated (Inadequate/low enrollment)
First Posted : October 24, 2018
Last Update Posted : May 28, 2020
Sponsor:
Information provided by (Responsible Party):
NYU Langone Health

Brief Summary:
The purpose of this study is to determine the efficacy of blood restriction therapy by comparing increase in muscle mass and strength in patients that receive blood restriction therapy to patients who receive a placebo.

Condition or disease Intervention/treatment Phase
Patellofemoral Pain Syndrome Procedure: Placebo Procedure: Personalized Tourniquet System for Blood Flow Restriction Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Primary Purpose: Treatment
Official Title: Blood Flow Restriction Therapy in Patellofemoral Pain Syndrome
Actual Study Start Date : February 1, 2019
Actual Primary Completion Date : November 1, 2019
Actual Study Completion Date : November 1, 2019

Arm Intervention/treatment
Experimental: Patients with Patellopain syndrome with Cuff
Patient will be prescribed to 6 weeks of physical therapy with a cuff around the affected leg during exercises
Procedure: Personalized Tourniquet System for Blood Flow Restriction
Patients will be receiving blood flow restriction therapy with a pressure cuff

Placebo Comparator: Patients with Patellopain syndrome with Placebo Cuff Procedure: Placebo
Patients will be receiving blood flow restriction therapy with a pressure cuff set to a placebo pressure setting.




Primary Outcome Measures :
  1. Increase in Muscle Mass Measured by Biodex [ Time Frame: 6 Weeks ]
    Biodex dynamometer is used under standard of care to measure the extensor strength of both legs and have bilateral thigh circumference measured

  2. Decrease in Pain measured by Visual Analog Scale (VAS) [ Time Frame: 6 Weeks ]
    100-mm horizontal line anchored at one end with the words "no pain" and at the other end with the words "worst pain imaginable."



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ASA class I-II
  • Diagnosed with patellofemoral pain syndrome

Exclusion Criteria:

  • Patients with confirmed radiographic evidence explaining knee pain
  • Legally incompetent or mentally impaired (e.g. minors, Alzheimer's subjects, dementia, etc.)
  • Younger than 18 years of age or older than 65
  • Any patient considered a vulnerable subject
  • Patients with impaired circulation, peripheral vascular compromise, Previous revascularization of the extremity, or severe hypertension
  • Patients with Sickle cell anemia or venous thromboembolism
  • Patients with Sickle cell anemia or venous thromboembolism
  • Patients with cancer or Lymphectomies
  • Patients with increased intracranial pressure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03717532


Locations
Layout table for location information
United States, New York
NYU Langone Health
New York, New York, United States, 10016
Sponsors and Collaborators
NYU Langone Health
Investigators
Layout table for investigator information
Principal Investigator: Guillen Gonzalez-Lomas, MD NYU Langone Medical Center
Layout table for additonal information
Responsible Party: NYU Langone Health
ClinicalTrials.gov Identifier: NCT03717532    
Other Study ID Numbers: 18-01123
First Posted: October 24, 2018    Key Record Dates
Last Update Posted: May 28, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Supporting Materials: Study Protocol
Time Frame: Beginning 3 months and ending 5 years following article publication.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Patellofemoral Pain Syndrome
Syndrome
Somatoform Disorders
Disease
Pathologic Processes
Mental Disorders
Joint Diseases
Musculoskeletal Diseases